Watch for the filing of the Form S-4 and proxy statement/prospectus, which will provide details on the shareholder vote and regulatory timeline. Monitor for any competing bids or regulatory pushback, particularly under the HSR Act. The expected close in H1 2027 and the $300M synergy target are key milestones to track.
Price Chart
Executive Summary
C.H. Robinson (CHRW) announced a definitive agreement to acquire RXO (RXO) in a stock-and-cash transaction valued at an implied $5.8 billion. RXO stockholders will receive $17.25 in cash and 0.0856 CHRW shares per RXO share, with an implied total consideration of $30.25 per share, representing a 27% premium to RXO's 90-day VWAP. The combined company is expected to generate approximately $300 million in net run-rate cost synergies within two years post-close and be accretive to adjusted EPS within nine months.
Key Financial Metrics
Key Facts
- C.H. Robinson to acquire RXO for implied total consideration of $30.25 per share, consisting of $17.25 cash and 0.0856 CHRW shares.
- Implied transaction value of $5.8 billion; combined enterprise value over $25 billion.
- Expected to generate ~$300 million in net run-rate cost synergies within two years post-close.
- Transaction expected to close in the first half of 2027, subject to regulatory and RXO stockholder approval.
- C.H. Robinson secured a $4.5 billion fully underwritten bridge facility from Morgan Stanley.
- RXO stockholders may elect all-cash ($30.25), all-stock (0.1992 CHRW shares), or standard mixed consideration, subject to proration targeting ~57% cash / 43% stock.
- MFN Partners, holding ~17.04% of RXO shares, entered into a voting and support agreement to vote in favor of the transaction.
- Transaction unanimously approved by both companies' boards of directors.
Financial Impact
Implied transaction value of $5.8 billion; combined enterprise value over $25 billion; ~$300 million net run-rate cost synergies expected within two years.
Risk Factors
- Regulatory approval risk under the HSR Act and other antitrust laws; failure to obtain approvals could delay or block the transaction.
- Integration risk: achieving the projected $300 million in cost synergies within two years may be challenging.
- Financing risk: although a $4.5B bridge facility is committed, market conditions could affect permanent financing terms.
- RXO stockholder approval required; though MFN Partners (~17%) has agreed to vote in favor, other shareholders may dissent.
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-413203 |
| Document: d115124d8k.htm | 0001193125-26-413203 |
| Document: d115124dex101.htm | 0001193125-26-413203 |
| Document: d115124dex991.htm | 0001193125-26-413203 |
| Document: d115124dex992.htm | 0001193125-26-413203 |
| Document: 0001193125-26-413203-index-headers.html | 0001193125-26-413203 |
| Document: 0001193125-26-413203-index.html | 0001193125-26-413203 |
| Document: 0001193125-26-413203.txt | 0001193125-26-413203 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Institutional Cluster | $139.66 | awaiting T+1 | awaiting T+1 | $143.59 (+2.81%) |
Oct 23, 2026 4d ago | Institutional Cluster | $141.17 $140.15 | ▲ +0.72% | ▲ +1.43% | $143.59 (−1.71%) |
Oct 5, 2026 22d ago | 8-K | $140.61 $135.05 | ▼ −3.95% | ▼ −4.50% | $143.59 (+2.12%) |
Jul 24, 2026 13w ago | 8-K | $186.51 $174.46 | ▲ +6.46% | ▲ +6.48% | $143.59 (+23.01%) |
Jun 14, 2026 19w ago | Institutional Cluster | $190.25 $189.40 | ▼ −0.45% | ▲ +0.15% | $143.59 (−24.53%) |
Feb 28, 2026 34w ago | Institutional Cluster | $186.60 $192.66 | ▲ +3.25% | ▲ +4.16% | $143.59 (−23.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers